Condition: Advanced Solid Tumor · Sponsor: Strand Therapeutics Inc.
Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab. The study now includes a monotherapy cohort targeting visceral lesions and a separate Phase 2 monotherapy cohort for advanced melanoma.
This description comes directly from the study's public registry record.
S Thomas, MS · 617-993-9281 · stx001.inquiry@strandtx.us
Always discuss trial participation with your own doctor first.
| HonorHealth Research and Innovation Institute | Scottsdale, Arizona, United States | Not Yet Recruiting |
| NextGen Oncology | Beverly Hills, California, United States | Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Not Yet Recruiting |
| University of Pittsburgh Medical Center | Pittsburgh, Pennsylvania, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Huntsman Cancer Institute - University of Utah | Salt Lake City, Utah, United States | Not Yet Recruiting |
| Melanoma Institute Australia | Wollstonecraft, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06249048